Pioglitazone, a thiazolidinedione, improves insulin sensitivity and thus reduces blood glucose. Clinical trials have suggested potential cardiovascular outcome benefits in association with pioglitazone; however, safety concerns are mounting, with recent data suggesting a link between pioglitazone and an increased risk of bladder cancer. There is thus a growing focus on the risk-benefit profile of this agent and hence its potential role in the blood glucose-lowering treatment algorithm for people with type 2 diabetes. There are clear potential outcome benefits associated with pioglitazone. In this review, the authors focus on putting the true risk-benefit profile of pioglitazone into context based on critical appraisal of the currently available evidence.
INTRODUCTION
Pioglitazone is the only thiazolidinedione (TZD) that is currently available in Europe. During the last few years, the focus has been on the sideeffect profile of this group of medications. In 2007, following a meta-analysis by Nissen et al. [1] on the cardiovascular safety of rosiglitazone, it was shown that rosiglitazone was associated with cardiovascular risk in terms of increased risk of myocardial infarction (MI). Further to this, the US Food and Drug Administration (FDA) have given strict criteria for new prescriptions and additional warning labeling for rosiglitazone. The European Medicine Agency (EMA) has withdrawn the marketing authorization for rosiglitazone. Of late, concerns have also been raised regarding a possible link between pioglitazone use and bladder cancer [2] [3] [4] . Here, the authors review the risk-benefit profile of pioglitazone, with a particular focus on the putative link between pioglitazone and bladder cancer.
METHODS
English language articles were included in the literature search, including the key terms ''pioglitazone,'' ''bladder cancer,'' and ''type 2 diabetes.'' The literature search included clinical trials, preclinical trials, and epidemiology and evidence reviews. to assess the change in percent atheroma volume in patients with type 2 diabetes and coronary artery disease, and the study compared pioglitazone with glimepiride [10] . In total, 360 patients completed the final IVUS assessment at 18 months, which showed that pioglitazone-treated patients had a significantly lower rate of progression of coronary atherosclerosis, compared with patients treated with glimepiride. Both these studies have used surrogate markers to assess the effect of pioglitazone on atherosclerosis, which has shown that the pioglitazone slows the progression of atherosclerosis compared to an active comparator (sulfonylurea).
PIOGLITAZONE AND CARDIOVASCULAR OUTCOME
In summary, pioglitazone appears to be associated with potential cardiovascular outcome benefits (Table 1 ) [5] [6] [7] [8] [9] [10] .
HEART FAILURE
Heart failure is the most commonly recognized side effect of pioglitazone. TZDs cause fluid retention and peripheral edema, predisposing the susceptible patients to heart failure. No detrimental effect on left ventricular function has been shown with TZDs. The pioglitazone meta-analysis revealed that serious heart failure was reported in 200 (2.3%) of pioglitazone-treated patients, compared with 139 (1.8%) of the control patients (HR = 1.41; 95% CI, 1.14-1.76; P = 0.002), but the composite endpoint of death and serious heart failure was not statistically different in the two groups [5] . The data from the PROactive study specifically looking at pioglitazone use and heart failure (PROactive 08) also showed a significant increase in heart failure in pioglitazone-treated patients, but subsequent analysis of patients who developed serious heart failure has shown that the all-cause mortality was proportionately lower with the pioglitazone group (40/149; 26.8%) compared with the placebo group (37/108; 34.3%) (P = 0.1338) [7] . The composite endpoint of death, nonfatal MI, or stroke was much less in pioglitazone patients with serious heart failure (34.9%) compared with placebo (47.2%), which was statistically significant (P = 0.025).
PIOGLITAZONE AND BLADDER CANCER
Experimental studies have reported that peroxisome proliferator-activated receptor (PPAR) agonists like pioglitazone and dual PPAR gamma/PPAR alpha agonists like muraglitazar induce urothelial bladder tumors [12] . Initial studies suggested that this is a ratspecific phenomenon [11] . Two mechanisms were postulated for this phenomenon.
Urothilium has plenty of PPAR gamma receptors, and direct interaction of the agonist with the receptors ultimately leading to induction of cancer was one possible mechanism suggested. But it has been shown that even though the PPAR gamma expression was at similar levels in rat and mouse urothelium, the TZD produced bladder tumors only in the rat and not in the mouse. In-vitro studies using human urothelial cell lines have shown that PPAR gamma agonists inhibit cell proliferation, hence a direct carcinogenic effect to the urothelium by the PPAR gamma agonist is less likely [11] . Also, as PPAR agonists are highly lipophilic, only a small percentage of administered drugs get excreted in the urine, reducing the exposure of the drug to the urothelium. The second postulated mechanism involves alteration to the urinary composition leading to cytotoxicity, necrosis, and urothelial [11] . This is associated with increased urothelial injury, necrosis, and regenerative proliferation. The amount of urinary solids detected in rats treated with pioglitazone was less than that observed for rats treated with muraglitazar [11] . As expected, muraglitazar induced a significantly higher incidence of bladder tumors than the small number induced by pioglitazone. The evidence from experimental studies supports the hypothesis that potential cytotoxicity may be related to urinary solids, namely calcium containing crystals and calculi [11] .
An interim report of a longitudinal cohort study conducted between 1997 and 2002, that assessed the risk of bladder cancer among diabetic patients treated with pioglitazone (including 193,099 patients in the Kaiser Permanente Northern California Diabetes Registry, [40 years of age) showed that after adjusting for age, sex, tobacco use, and use of other categories of diabetes medications, there was no significant increase in the risk of bladder cancer in patients ever exposed to pioglitazone, compared with patients never exposed to pioglitazone (HR = 1.2; 95% CI, 0.9-1.5), with similar results in men and women [12] .
However, the risk of bladder cancer rose with increasing duration of pioglitazone use.
Compared to never being used, pioglitazone treatment for more than 24 months was associated with a 40% increase in relative risk of developing bladder cancer (HR = 1.4; 95% CI, 0.9-2.1). Based on these data, the FDA calculated that duration of therapy longer than 12 months was associated with 27.5 excess cases of bladder cancer per 100,000 person-years follow-up, compared with no use of pioglitazone [13] . and acarbose being small, it is too susceptible to reporting biases, and hence not clinically relevant. But this report concluded that there was a definite signal for bladder cancer associated with pioglitazone use [11] .
A retrospective cohort study using the data from the French National Health Insurance System also showed an increased risk of bladder cancer with pioglitazone use [12] . This study was from a cohort of 1,491,060 diabetes patients on drug therapy, aged 40-79, followed-up for up to 4 years (2006-2009) . Of these, 155,535 patients were pioglitazone treated. The results showed that after adjusting for age, sex, and use of other antidiabetic medications, there was a statistically significant increase in the risk of bladder cancer in patients exposed to pioglitazone, compared with patients exposed to other antidiabetic agents (HR = 1.22; 95% CI, 1.03-1.43). The results also showed a dose effect related to cumulative dose [28,000 mg (HR = 1.75; 95% CI, 1.22-2.5) and for exposure longer than 1 year (HR = 1.34; 95% CI, 1.02-1.75). A significant increase in risk was observed in males (HR = 1.28; 95% CI, 1.09-1.51) [13] .
FRACTURE RISK
TZDs affect the bone homeostasis adversely.
Mesenchymal stem cells in the bone act as the common progenitor of both adipocytes and osteoblasts [15] . TZD alters the maturation of mesenchymal stem cells. This affects the bone density and osteoblast functioning, which leads to reduced osteoblast activity, shifting the balance of bone homeostasis to favor bone loss.
Clinical studies have shown an increased risk of fractures, especially in females. In the PERISCOPE study, fractures occurred in 3% of patients treated with pioglitazone, compared with none in the glimepiride group [7] . 
REGULATORY CONSIDERATIONS FOR PIOGLITAZONE
Following the retrospective study conducted by the National Health Insurance Agency, the
French agency for drug regulations (AFSSAPS)
have suspended the use of pioglitazone in
France since June 2011 [17] .
The FDA safety communication in June 2011 announced that the use of pioglitazone for more than 1 year may be associated with an increased risk of bladder cancer [13] . It recommended not to use pioglitazone in patients with active bladder cancer, and to evaluate risks and benefits before initiating pioglitazone [3] . The FDA encourages physicians to counsel patients regarding the symptoms of bladder cancer [3] .
In July 2011, the EMA concluded that the evidence from different sources showed a small increased risk of bladder cancer with pioglitazone, in particular in patients treated for the longest durations and with the highest cumulative doses [2] . The EMA advised the clinicians not to use pioglitazone in patients with a past or current history of bladder cancer or in patients with uninvestigated macroscopic hematuria. Various risk factors for bladder cancer (elderly people, smoking, previous exposure to occupational risk factors, or drugs related to a risk of bladder cancer) should be assessed before initiating pioglitazone. The balance of risk and benefits should be assessed before as well as during treatment with pioglitazone, to ensure that only patients who are deriving sufficient benefit continue to take it.
CONCLUSION
Pioglitazone remains a useful blood glucoselowering therapy and may produce significant clinical benefits for some patients, particularly from the perspective of potential cardiovascular outcomes. It would therefore be inappropriate to recommend discontinuation of pioglitazone use for all patients. A number of safety concerns have been identified with pioglitazone, including an increased risk of cardiac failure, bone fracture, and a small but definite increase in the risk of bladder cancer. Thus, when considering the use of pioglitazone, an individualized patient risk-benefit evaluation is essential with the use of pioglitazone being inappropriate in people considered at risk of bone fracture, cardiac failure, or bladder cancer.
